Research Analysts Issue Forecasts for Ocugen Q3 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Ocugen in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.07) per share for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Ocugen’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.36) EPS, FY2028 earnings at ($0.41) EPS, FY2029 earnings at $0.14 EPS and FY2030 earnings at $1.08 EPS.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.49 million during the quarter, compared to the consensus estimate of $0.89 million.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group reduced their target price on shares of Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded shares of Ocugen from a “hold” rating to a “sell” rating in a research report on Saturday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Ocugen Stock Up 2.3%

Shares of Ocugen stock opened at $1.31 on Tuesday. The firm has a market cap of $444.23 million, a PE ratio of -5.04 and a beta of 2.21. The business’s 50 day simple moving average is $1.34 and its 200 day simple moving average is $1.56. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.80 and a current ratio of 0.80. Ocugen has a 52-week low of $0.96 and a 52-week high of $2.73.

Insider Buying and Selling

In other news, CFO Treerita Essali Johnson-Greene bought 21,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were bought at an average cost of $1.23 per share, with a total value of $25,830.00. Following the acquisition, the chief financial officer owned 521,000 shares in the company, valued at $640,830. This trade represents a 4.20% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.95% of the stock is currently owned by corporate insiders.

Institutional Trading of Ocugen

Several institutional investors and hedge funds have recently bought and sold shares of the business. Diversify Advisory Services LLC acquired a new stake in shares of Ocugen in the second quarter valued at approximately $25,000. SmartHarvest Portfolios LLC bought a new stake in Ocugen in the 4th quarter valued at $31,000. CTC Alternative Strategies Ltd. acquired a new stake in Ocugen during the 1st quarter valued at $34,000. BNP Paribas Financial Markets lifted its holdings in Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after purchasing an additional 13,326 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in Ocugen by 198.0% during the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after purchasing an additional 24,460 shares during the period. Institutional investors own 10.27% of the company’s stock.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Negative Sentiment: HC Wainwright cut its estimates across several periods. The firm lowered its FY2026 EPS forecast to a loss of $0.28 from $0.25, FY2027 to a loss of $0.36 from $0.26, and FY2028 to a loss of $0.41 from a prior estimate of $0.05. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, pointing to a longer period of expected operating losses. Ocugen analyst estimate report
• Negative Sentiment: Long-term earnings expectations were sharply downgraded. HC Wainwright reduced its FY2029 EPS forecast to $0.14 from $0.61 and FY2030 to $1.08 from $1.56. Although the estimates still imply a potential return to profitability, the much lower projections weaken the longer-term earnings outlook.
• Negative Sentiment: Noble Financial also lowered its forecasts. Noble cut its FY2026 EPS estimate to a loss of $0.26 from $0.22 and reduced Q3 2026 EPS to a loss of $0.06 from $0.05 and Q4 2026 to a loss of $0.07 from $0.06. These revisions reinforce concerns about near-term cash consumption and execution.
• Neutral Sentiment: The broader earnings picture remains speculative. Ocugen is expected to remain unprofitable in the near term, while the available estimates project profitability beginning in FY2029. With OCGN trading near its 50-day average and well below its one-year high, investor focus is likely to remain on clinical progress, funding needs and the company’s ability to convert its pipeline into revenue.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.